Loading
Pluri Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 01 Jul 2025.
Pluri Inc.: what insiders have been doing
This page follows insider dealings at Pluri Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Haifa, United States. The group dates from 2001. From 18 October 2025 to 18 October 2026, the disclosure feed for Pluri Inc. logged 13 filings by 8 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Compared with its exchange (5,458 companies, median 22 filings), a count of 13 filings is below the norm. Looking back to 2016, when coverage begins, insiders filed 5 purchases and 4 sales.
No insider has bought Pluri Inc. shares on the open market in the past twelve months. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
51
Thresholds
n/a
Buy Volume
€2M
5 ops. · all time
Sell Volume
€1M
4 ops. · all time
Who traded when
BuySaleAlexandre Weinstein Manieu1 buy
Since the insiders bought
- -60.9%Entry US$5.39 · Close at T+365 US$2.11
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended June 2026 · cache
US$0.94
Analyst consensus
1 analystsUS$12.00Target US$12.00(+1177%)US$12.00
Income statement
RevenueUS$1M
Gross profitUS$453k45% margin
EBITDA-US$24M-2357% margin
Net income-US$23.8M-2344.6% margin
Valuation
Beta0.69
Balance sheet & cash
Market capUS$11.9M
Total debtUS$34.9M
Free Cash Flow-US$20.2M
Profitability & ownership
ROA-49.0%
% insiders42.5%
% institutions20.7%
Last declaration on 24 August 2026
Declarations51 total
180,000 shares0Common SharesSEC:0001213900-26-093064:0
31,569 shares0Common StockSEC:0001213900-26-093070:0
312,500 shares@ US$2.003.65% mcap14.5% of flowCommon StockSEC:0001213900-26-051531:0
625,000 shares@ US$2.0028.8% of flowCommon StockSEC:0001213900-26-001394:0
346 shares0Common StockSEC:0001213900-25-119229:0
668 shares0Common StockSEC:0001213900-25-119235:0
6,588 shares0Common StockSEC:0001213900-25-119234:0
653 shares0Common StockSEC:0001213900-25-119233:0
3,660 shares0Common StockSEC:0001213900-25-119232:0
699 shares0Common StockSEC:0001213900-25-119230:0
519 shares0Common StockSEC:0001213900-25-119238:0
10,250 shares0Common StockSEC:0001213900-25-112942:0
11,685 shares0Common StockSEC:0001213900-25-109609:0
39,050 shares0Common StockSEC:0001213900-25-099642:0
523,437 shares@ US$4.6156.7% of flowCommon StockSEC:0001213900-25-060346:0
Canonical exit: 27 Jul 2025 (T+90)
181,900 shares0Common StockSEC:0001213900-25-017976:0
11,173 shares0Common StockSEC:0001213900-25-017973:0
10,250 shares0Common StockSEC:0001213900-25-017970:0
14,350 shares0Common StockSEC:0001213900-25-017971:0
67,857 shares0Common StockSEC:0001213900-25-017972:0
11,685 shares0Common StockSEC:0001213900-25-017969:0
11,173 shares0Common StockSEC:0001213900-25-017975:0
25,240 shares0Common StockSEC:0001213900-24-080652:0
8,413 shares0Common StockSEC:0001213900-24-080648:0
44,100 shares0Common StockSEC:0001213900-24-006454:0
25 of 51 declarations
About Pluri Inc.
Pluri Inc. is a U.S.-listed biotechnology company trading on the NASDAQ under the ticker PLUR. It is incorporated in the United States, while its main operational base and research footprint are in Haifa, Israel, giving the company an international operating profile. Founded in 2003, Pluri has built its business around a proprietary 3D cell-expansion platform designed to grow cells at scale in a standardized, reproducible, and potentially cost-efficient way. For investors, the company is best viewed as a platform-driven biotech rather than a conventional single-product drug developer: Pluri aims to apply one core cell-engineering capability across several commercial verticals.
Historically, Pluri’s core focus has been regenerative medicine and cell therapy. The company develops allogeneic, placenta-derived product candidates and describes a pipeline aimed at major unmet medical needs in areas such as vascular disease, inflammation-related disorders, muscle injuries, and hematological conditions. A key element of its strategy is an in-house GMP manufacturing facility, which supports process control, product consistency, and eventual scale-up. In cell therapy, manufacturing know-how is often as important as the scientific concept itself, so this operational asset is strategically meaningful.
Read moreShow less
Pluri has also broadened its scope beyond healthcare into adjacent markets through venture-building and strategic partnerships. The company has initiatives in food-tech and agtech, including cultivated cacao through Kokomodo and cultivated meat-related activity through Ever After Foods. This diversification potentially expands the addressable market and creates additional monetization paths for the same core technology, but it also increases execution risk and capital demands. Competitively, Pluri’s value proposition rests on three pillars: proprietary intellectual property, scalable cell-production capabilities, and the ability to form partnerships that convert a technology platform into commercial opportunities.
Geographically, Pluri combines Israeli R&D depth with access to U.S. capital markets through NASDAQ. Recent developments have been important for investors following the name. In 2025 and 2026, the company highlighted new patent progress, including patent protection in China for its 3D immune cell expansion and activation technology, and it announced a $2.5 million additional investment from an entity beneficially owned by Chairman Alejandro Weinstein in March 2026. In January 2025, Pluri also disclosed a $6.5 million strategic investment and the acquisition of a majority stake in Kokomodo. Taken together, these updates point to a company actively trying to strengthen its balance sheet, defend its intellectual property, and build optionality across biotech and adjacent cell-based industries in the United States and abroad.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
